FDA Seeks To Write MedGuides Outside REMS Process
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency advice on REMS evolves as FDA gains experience with the program, OSE Director Dal Pan says at DIA.
You may also be interested in...
New Drugs Get "Luck Of The Draw" In FDA's First Round Of 18-Month Reviews
"We're not being surprised by anything we are seeing" in the initial batch of FDAAA-mandated post-market assessments, FDA's Boucher says.
Earlier Attention To REMS Could Keep Drug Approvals On Schedule, Industry Says At FDA Meeting
BIO member survey finds 77 percent of firms with REMS report that risk discussions prolonged product reviews.
REMS Must Be Designed With Input From Doctors, Kaiser Tells FDA In Petition
Kaiser Permanente is pressing FDA to open up the process for creating Risk Evaluation and Mitigation Strategies to a broader audience